A Multicenter, Long-Term Extension Study of 104 Weeks, Including a Double-Blind, Placebo-Controlled 40-Week Randomized Withdrawal-Retreatment Period, to Evaluate the Maintenance of Treatment Effect of Ixekizumab (LY2439821) in Patients With Axial Spondyloarthritis
收藏DataCite Commons2025-10-02 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00007577/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to evaluate, in participants having achieved a state of
sustained remission, if the ixekizumab treatment groups are superior to the placebo group in
maintaining response during the randomized withdrawal-retreatment period in participants with
axial spondyloarthritis.
提供机构：
Vivli
创建时间：
2021-12-23
